APR Applied Pharma Research SA, a company that deals with the development of technologies and distribution systems for pharmaceutical drugs and innovative products derived from them, announced on Thursday that it has commenced a study primary clinician to assess the effectiveness of its product codename APR-AOS2020, a class III medical device, intended to treat COVID-19 patients with moderate symptoms.
The company is conducting the study at the hygiene unit of the Hospital IRCCS Policlinico San Martino in Genoa, Italy, coordinated by Prof Giancarlo Icardias, principal investigator.
The study will enrol a total of 57 patients with COVID-19 who have mild symptoms of the disease and will assess the efficacy and safety of the spray product in reducing viral load in the upper respiratory tract in newly infected individuals. The results are hoped to represent the starting point for the use of the product in the prevention of more serious symptoms, in decreasing the risk of infection and spread of the virus.
Charles River Laboratories launches AMAP to reduce animal testing reliance
PureTech completes enrollment in Phase 2b ELEVATE IPF trial for LYT-100
Cybin secures additional US patent for CYB003 breakthrough therapy programme
GSK's meningitis vaccine candidate accepted for FDA review
Innovent Biologics names new Oncology CMO
UroGen's UGN-103 IND accepted by FDA for bladder cancer treatment
Biophytis reinforces obesity IP with new patent application
MaaT Pharma reveals positive 18-month data for MaaT013 in GI-aGvHD
Fusion Antibodies plc secures contract for OptiPhage library development
Innate Pharma advances Sanofi-developed NK cell engager to Phase 2 for blood cancer patients
AbbVie announces interim evaluation of Atogepant Phase three, open-label 156-week extension study